Evogene (EVGN) Asset Utilization Ratio (2025 - 2026)

Evogene (EVGN) posted Asset Utilization Ratio of 0.18 for Q1 2026, up 10.04% sequentially from 0.17 in Q4 2025, and up 9.4% YoY from 0.17 in Q1 2025.

Evogene (EVGN) Asset Utilization Ratio (2025 - 2026) Analysis & Trends

Evogene has reported Asset Utilization Ratio for 2 years, with the latest figure at 0.18 in Q1 2026.

Quarterly Asset Utilization Ratio rose 9.4% year-over-year to 0.18 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.18 (up 9.4% YoY) and the FY2025 annual result came in at 0.13, up 4.9% from the prior year.
Asset Utilization Ratio rose to 0.18 in Q1 2026 per EVGN's latest filing, from 0.17 in the prior quarter.
Over five years, Asset Utilization Ratio peaked at 0.19 in Q2 2025 and troughed at 0.17 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Asset Util. (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	0.47
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	0.38
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	0.20
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	0.69
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	0.90
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	0.13
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	0.54
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	0.13
10	Evogene	4.38 Mn	4.38 Mn	204,000.00	0.18

Download Data